It's a healthcare platform that lets users talk to doctors and buy generic treatments for various sensitive and embarrassing conditions like baldness and weight. Shares soared 30% when it reported Q4 last February, then kept rising. They reported strong growth, profits and guidance. They reported another beat in May, because they were offering more products, namely weight-loss drugs, including GLP-1 injections which are in high demand. But these aren't the patented drugs from Eli Lilly and Novo Nordisk, but copycats (legal) at a much lower price. Shares jumped on this May 20 news. Then in late June a media report stated that HIMS was getting this drug from a supplier that had previously unreported, ties to fraud and bankruptcy, and that users can get these drugs without a prescription, which opens HIMS to litigation risk. Shares fell back to $20, which is an attractive level to enter. He has mixed feelings. The company was good before GLP-1 and good overall.
Hims & Hers Health is a American stock, trading under the symbol HIMS-N on the New York Stock Exchange (HIMS). It is usually referred to as NYSE:HIMS or HIMS-N
In the last year, 2 stock analysts published opinions about HIMS-N. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Hims & Hers Health.
Hims & Hers Health was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Hims & Hers Health.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Hims & Hers Health published on Stockchase.
On 2024-10-22, Hims & Hers Health (HIMS-N) stock closed at a price of $23.59.
Likes it. Is up 129% this year, but isn't expensive, considering all its growth.